中国生物制药7月15日发布公告称将以约5亿美元的总价收购上海礼新医药95.09%股权加上此前参与礼新C轮融资时已取得的4

智通财经
Jul 15, 2025
中国生物制药7月15日发布公告称将以约5亿美元的总价收购上海礼新医药95.09%股权加上此前参与礼新C轮融资时已取得的4.91%股权交易完成后礼新医药将成为中国生物制药全资子公司。有市场传言称此前礼新与默沙东就PD-1/VEGF双特异性抗体LM-299达成的授权协议疑遭“退货”。对此中国生物制药回应称礼新与默沙东的合作根据许可协议在正常有序地推进中。“目前我们正在推进技术转移根据交易合同约定完成技术转移后礼新将收到3亿美金的技术转移的里程碑付款根据默沙东此前新闻稿披露预计此项技术转移将在2025年内完成。” 中国生物制药表示。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10